An overview of long non-coding RNAs in ovarian cancers

Matthieu Meryet-Figuière _, Bernard Lambert, Pascal Gauduchon, Nicolas Vigneron, Emilie Brotin, Laurent Poulain and Christophe Denoyelle

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:44719-44734. https://doi.org/10.18632/oncotarget.8089

Metrics: PDF 2794 views  |   HTML 2698 views  |   ?  


Matthieu Meryet-Figuière1,2,3,4, Bernard Lambert1,2,3,4,5, Pascal Gauduchon1,2,3,4, Nicolas Vigneron1,2,3,4, Emilie Brotin1,2,3,4, Laurent Poulain1,2,3,4 and Christophe Denoyelle1,2,3,4

1 Inserm U1199, Biology and Innovative Therapeutics for Locally Aggressive Cancer (BioTICLA) Unit, Caen, France

2 Normandie University, Caen, France

3 UNICAEN, Caen, France

4 Comprehensive Cancer Center CLCC François Baclesse, Unicancer, Caen, France

5 CNRS, Paris, France

Correspondence to:

Matthieu Meryet-Figuière, email:

Keywords: IncRNA, ovarian cancer

Received: November 06, 2015 Accepted: February 23, 2016 Published: March 15, 2016


As with miRNAs a decade ago, the scientific community recently understood that lncRNAs represent a new layer of complexity in the regulation of gene expression. Although only a subset of lncRNAs has been functionally characterized, it is clear that they are deeply involved in the most critical physiological and pathological biological processes. This review shows that in ovarian carcinoma, data already available testify to the importance of lncRNAs and that the demonstration of an ever-growing role of lncRNAs in the biology of this malignancy can be expected from future studies. We also underline the importance of their relationship with associated protein partners and miRNAs. Together, the available information suggests that the emerging field of lncRNAs will pave the way for a better understanding of ovarian cancer biology and might lead to the development of innovative therapeutic approaches. Moreover, lncRNAs expression signatures either alone or in combination with other types of markers (miRNAs, mRNAs, proteins) could prove useful to predict outcome or treatment follow-up in order to improve the therapeutic care of ovarian carcinoma patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8089